Skip to main content

Encouraging prospects with sugemalimab in relapsed or refractory extranodal natural killer/T-cell lymphoma.

Publication ,  Journal Article
Shi, W; Lu, T; Xu-Monette, Y; Young, KH
Published in: Chin Clin Oncol
February 2024

Duke Scholars

Published In

Chin Clin Oncol

DOI

EISSN

2304-3873

Publication Date

February 2024

Volume

13

Issue

1

Start / End Page

17

Location

China

Related Subject Headings

  • Retrospective Studies
  • Prognosis
  • Lymphoma, T-Cell
  • Lymphoma, Extranodal NK-T-Cell
  • Killer Cells, Natural
  • Humans
  • Biomarkers, Tumor
  • Antibodies, Monoclonal, Humanized
  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Shi, W., Lu, T., Xu-Monette, Y., & Young, K. H. (2024). Encouraging prospects with sugemalimab in relapsed or refractory extranodal natural killer/T-cell lymphoma. Chin Clin Oncol, 13(1), 17. https://doi.org/10.21037/cco-23-69

Published In

Chin Clin Oncol

DOI

EISSN

2304-3873

Publication Date

February 2024

Volume

13

Issue

1

Start / End Page

17

Location

China

Related Subject Headings

  • Retrospective Studies
  • Prognosis
  • Lymphoma, T-Cell
  • Lymphoma, Extranodal NK-T-Cell
  • Killer Cells, Natural
  • Humans
  • Biomarkers, Tumor
  • Antibodies, Monoclonal, Humanized
  • 3211 Oncology and carcinogenesis